Glumate and Disorders of Cognition and Motivation

描述（由申请人提供）：尽管谷氨酸介导的神经传递长期以来与神经退行性疾病有关，但对认知、情感和成瘾疾病的研究主要集中在大脑中的单胺（多巴胺、血清素、去甲肾上腺素）系统上。由于谷氨酸在皮质功能中的重要性，以及谷氨酸能投射控制单胺能神经元的活动，关于谷氨酸在情感性和成瘾性疾病中的可能作用的研究开始于10-15年前，并使我们对谷氨酸在这些疾病中的作用的理解取得了重大进展。纽约科学院正在赞助一个为期2.5天的会议，计划于2003年4月13日至15日在康涅狄格州纽黑文举行，会议的主题是“谷氨酸与认知和动机障碍”。会议的目的是将研究谷氨酸在认知障碍（如精神分裂症）和与动机和情感有关的障碍（如抑郁症和成瘾）中的作用的基础和临床研究人员聚集在一起。本次会议将为基础和临床领域的前沿研究提供一个展示的场所。通过促进基础科学家和临床医生之间的互动，它可能会加快我们在基本机制方面的知识进步转化为新药物治疗的速度。会议将分六次举行。第一次会议将回顾谷氨酸介导的信号传导基本方面的最新进展，并从解剖学、电生理学和信号转导的角度介绍单胺系统之间的相互作用，这是长期以来精神疾病和谷氨酸系统研究的重点。接下来的四次会议将围绕具体的疾病组织。会议将以以谷氨酸为基础的药物治疗从精神分裂症到成瘾等疾病的会议结束。除全体会议外，还将在两个下午举行海报会议。

DESCRIPTION (provided by applicant): Although glutamate-mediated neurotransmission has long been implicated in neurodegenerative disorders, the major focus of research on cognitive, affective and addictive disorders has been on monoamine(dopamine, serotonin, norepinephrine) systems in the brain. Because of glutamate's importance in cortical function, and because glutamatergic projections govern the activity of monoaminergic neurons, studies on the possible role of glutamate in affective and addictive disorders began 10-15 years and have led to significant advances in our understanding of glutamatergic involvement in these disorders. The New York Academy of Sciences is sponsoring a 2.5 day conference, scheduled for April 13-15, 2003, in New Haven, CT, titled "Glutamate and Disorders of Cognition and Motivation" The objective is to bring together diverse groups of basic and clinical researchers who study the role of glutamate in cognitive disorders such as schizophrenia, and disorders relating to motivation and affect, such as depression and addiction. This conference will provide a venue for presentation of cutting edge research in both basic and clinical fields. By facilitating interactions between basic scientists and clinicians, it may accelerate the rate at which advances in our knowledge of basic mechanisms can be translated into development of new pharmacotherapies. The conference will be organized in six sessions. The first session will review recent advances in basic aspects of glutamate-mediated signaling and present anatomical, electrophysiological and signal transduction perspectives on interactions between monoamine systems, long the focus of research on psychiatric disorders, and glutamate systems. The next four sessions will be organized around specific disorders. The meeting will close with a session on glutamate-based pharmacotherapies for disorders ranging from schizophrenia to addiction. In addition to the plenary sessions, poster sessions will be held on two afternoons.